Results 191 to 199 of about 10,848 (199)

Obinutuzumab Plus Chlorambucil in Patients With CLL and Coexisting Conditions

New England Journal of Medicine, 2014
Stephen Opat, Anton W Langerak, Stephan Stilgenbauer   +2 more
exaly  

Obinutuzumab

Reactions Weekly, 2018
openaire   +2 more sources

Obinutuzumab Induces Depletion of NK Cells in Patients With Chronic Lymphocytic Leukemia.

Immunotherapy, 2018
Elena Domínguez-Garrido, Carlos Panizo, Jesus Feliu   +2 more
exaly  

A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients With B-Cell Malignancies

Advances in Therapy, 2017
Christian Klein, Kensei Tobinai, Günter Fingerle-Rowson   +2 more
exaly  

Obinutuzumab or Tacrolimus in Primary Membranous Nephropathy.

New England Journal of Medicine
Ana Malvar, Jay P Garg, Theodore A Omachi   +2 more
exaly  

Obinutuzumab as a therapeutic option for SDNS children resistant to rituximab with anti-RTX antibodies.

Pediatric nephrology (Berlin, West)
Cyrielle Parmentier, Anne-Lise Mary, Antoine Diep, Julien Hogan, Tim Ulinski, S. Mignot, C. Dossier   +6 more
semanticscholar   +1 more source

Obinutuzumab

Reactions Weekly, 2017
openaire   +1 more source

Obinutuzumab

Reactions Weekly, 2014
openaire   +1 more source

Efficacy and safety of obinutuzumab on progressive IgA nephropathy: a case series

JN. Journal of Nephrology (Milano. 1992)
Qi Ding, Cheng Xue, Xiang Gao, Xiao-Jing Tang, Sanli Zhang, Ya-Wei Liu, Bing Dai   +6 more
semanticscholar   +1 more source